Bicyclic γ-amino acid derivative
AssigneeDaiichi Sankyo Company, Limited
InventorsKousei Shimada, Asuka Kawamura, Naohisa Arakawa, Yuki Domon
Life of this patent
Estimating the term…
Abstract
It is intended to provide a bicyclic γ-amino acid derivative having excellent activity as an α2δ ligand. The present invention provides a compound represented by the general formula (I): wherein R1, R2, R2′, R4, R5, R6, R7, R8, and R8′ are a hydrogen atom or the like; and R3 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or the like.
Claims20
A compound according to formula (I) or a pharmacologically acceptable salt thereof, wherein formula (I) is selected from the group consisting of:
- wherein
- R1, R2, R2′, R4, R5, R6, R7, R8, and R8′ are a hydrogen atom;
- and
- R3 is a hydrogen atom, a methyl group or an ethyl group.
A compound selected from the group consisting of:
- [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid;
- [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid hydrochloride;
- [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid;
- [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid p-toluenesulfonate;
- and
- [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid benzenesulfonate.
[(1R,5S,6S)-6-(aminomethyl)bicyclo [3.2.0]hept-3-en-6-yl]acetic acid.
[(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid hydrochloride.
[(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid p-toluenesulfonate.
[(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid benzenesulfonate.
A pharmaceutical composition comprising [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid as an active ingredient and a pharmaceutically acceptable additive.
A pharmaceutical composition comprising [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid hydrochloride as an active ingredient and a pharmaceutically acceptable additive.
A pharmaceutical composition comprising [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid p-toluenesulfonate as an active ingredient and a pharmaceutically acceptable additive.
A pharmaceutical composition comprising [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid benzenesulfonate as an active ingredient and a pharmaceutically acceptable additive.
A method of treating a disease or disorder selected from the group consisting of postherpetic neuralgia, neuropathic pain, diabetic neuropathic pain, and fibromyalgia comprising administering a compound or a pharmacologically acceptable salt thereof selected from the group consisting of [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid;
- [(1R,5S,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-3-en-6-yl]acetic acid hydrochloride;
- [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid p-toluenesulfonate;
- and [(1R,5S,6S)-6-aminomethyl-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid benzenesulfonate.
Dependencies are inferred from the claim text.